Literature DB >> 12213901

WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells.

Bilgin Gurates1, Siby Sebastian, Sijun Yang, Jianfeng Zhou, Mitsutoshi Tamura, Zongjuan Fang, Takashi Suzuki, Hironobu Sasano, Serdar E Bulun.   

Abstract

The orphan nuclear receptor steroidogenic factor-1 (SF-1) induces the expression of Müllerian inhibiting substance (MIS) and many steroidogenic genes, including aromatase P450 (P450arom). Dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on the X chromosome gene 1 (DAX-1) inhibits SF-1-mediated induction of MIS and other steroidogenic genes, whereas Wilms' tumor suppressor gene (WT1) augments SF-1-mediated MIS expression. The effects of WT1 on steroidogenesis or P450arom expression have not been explored to date. In human endometriotic stromal cells, extremely high levels of P450arom mRNA and enzyme activity are present. Prostaglandin E(2) stimulates cAMP formation, SF-1 binding activity, P450arom mRNA levels, and estrogen synthesis in endometriotic stromal cells. Stromal cells of eutopic endometrium from disease-free women, on other hand, do not contain readily detectable levels of P450arom mRNA. Thus, we evaluated herein the possible roles of WT1 and DAX-1 in cAMP/SF-1-mediated regulation of P450arom expression in endometriotic and endometrial stromal cells. We also determined the cellular distribution and levels of these transcription factors in pathological endometriotic vs. normal eutopic endometrial tissues by immunohistochemistry to understand their in vivo roles. In vitro transcriptional regulation studies showed that both WT1 and DAX-1 inhibited cAMP and/or SF-1-induced P450arom promoter activity in a dose-dependent fashion in cultured human endometriotic and endometrial stromal cells. Site-directed disruption of the SF-1 binding site (-136/-124 bp) in the P450arom promoter abolished basal or cAMP/SF-1-induced promoter activity in the presence or absence of WT1 or DAX-1. Immunohistochemistry and H-scoring showed that DAX-1 was ubiquitously present in epithelial and stromal cells of both tissues. WT1, on the other hand, was preferentially expressed in stromal (vs. epithelial) cells. Moreover, WT1 levels in endometriotic stromal cells are significantly down-regulated compared with normal endometrial stromal cells. In summary, WT1 or DAX-1 inhibits cAMP-SF-1 pathway-dependent P450arom expression in cultured human endometriotic and endometrial stromal cells. In vivo down-regulation of WT1 in endometriotic stromal cells (vs. normal endometrial stromal cells) may in part be responsible for aberrantly increased P450arom expression and estrogen formation in this pathological tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213901     DOI: 10.1210/jc.2002-020522

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

1.  Estrogen receptor-β and fetoplacental endothelial prostanoid biosynthesis: a link to clinically demonstrated fetal growth restriction.

Authors:  Emily J Su; Linda Ernst; Nadine Abdallah; Robert Chatterton; Hong Xin; Diana Monsivais; John Coon; Serdar E Bulun
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Cloning, characterization and function analysis of DAX1 in Chinese loach (Paramisgurnus dabryanus).

Authors:  Xiaohua Xia; Weiran Huo; Ruyan Wan; Peijin Wang; Zhongjie Chang
Journal:  Genetica       Date:  2018-09-11       Impact factor: 1.082

3.  Impaired fetoplacental angiogenesis in growth-restricted fetuses with abnormal umbilical artery doppler velocimetry is mediated by aryl hydrocarbon receptor nuclear translocator (ARNT).

Authors:  Emily J Su; Hong Xin; Ping Yin; Matthew Dyson; John Coon; Kathryn N Farrow; Karen K Mestan; Linda M Ernst
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 4.  Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response.

Authors:  Rebecca B Riggins; Mary M Mazzotta; Omar Z Maniya; Robert Clarke
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

5.  Aromatase inhibition for refractory endometriosis-related chronic pelvic pain.

Authors:  Fadi Abushahin; Kara N Goldman; Elizabeth Barbieri; Magdy Milad; Alfred Rademaker; Serdar E Bulun
Journal:  Fertil Steril       Date:  2011-08-24       Impact factor: 7.329

Review 6.  Aromatase inhibitors for the treatment of endometriosis.

Authors:  Mary Ellen Pavone; Serdar E Bulun
Journal:  Fertil Steril       Date:  2012-09-19       Impact factor: 7.329

7.  Cyclic adenosine 3',5'-monophosphate response element-binding protein and CCAAT/enhancer-binding protein mediate prostaglandin E2-induced steroidogenic acute regulatory protein expression in endometriotic stromal cells.

Authors:  Chih-Chao Hsu; Chun-Wun Lu; Bu-Miin Huang; Meng-Hsing Wu; Shaw-Jenq Tsai
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

8.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

9.  Regulation of Wilms' tumor gene expression by nerve growth factor and follicle-stimulating hormone in the immature mouse ovary.

Authors:  Jaesook Roh; Jeehyeon Bae; Kangseok Lee; Kelly Mayo; Lonnie Shea; Teresa K Woodruff
Journal:  Fertil Steril       Date:  2008-09-06       Impact factor: 7.329

10.  CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma.

Authors:  Hiroshi Ishikawa; Veysel Fenkci; Veysel Fencki; Erica E Marsh; Ping Yin; Dong Chen; You-Hong Cheng; Scott Reisterd; Zhihong Lin; Serdar E Bulun
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.